Esperion Therapeutics Inc. (NASDAQ:ESPR)’s share price fell 4.5% on Tuesday . The stock traded as low as $10.90 and last traded at $10.93, with a volume of 99,868 shares changing hands. The stock had previously closed at $11.44.

Several research firms recently weighed in on ESPR. Vetr downgraded Esperion Therapeutics from a “strong-buy” rating to a “buy” rating and set a $12.60 target price on the stock. in a research report on Monday. Credit Suisse Group AG reiterated a “sell” rating and set a $10.00 target price on shares of Esperion Therapeutics in a research report on Wednesday, July 6th. WallachBeth Capital downgraded Esperion Therapeutics from a “buy” rating to a “hold” rating and set a $35.00 price objective on the stock. in a research report on Tuesday, July 5th. Stifel Nicolaus downgraded Esperion Therapeutics from a “neutral” rating to an “underperform” rating and lowered their price objective for the company from $23.00 to $10.00 in a research report on Thursday, June 30th. Finally, Chardan Capital restated a “hold” rating and issued a $13.00 price objective on shares of Esperion Therapeutics in a research report on Wednesday, June 29th. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and six have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $25.47.

The firm has a 50 day moving average of $14.52 and a 200 day moving average of $15.88. The company’s market cap is $246.05 million.

Esperion Therapeutics (NASDAQ:ESPR) last announced its quarterly earnings results on Wednesday, May 4th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, topping the consensus estimate of ($0.74) by $0.09. Equities analysts predict that Esperion Therapeutics Inc. will post ($3.57) EPS for the current fiscal year.

In other news, Director Mark E. Mcgovern bought 5,000 shares of the stock in a transaction dated Wednesday, July 6th. The shares were acquired at an average cost of $10.00 per share, with a total value of $50,000.00. Following the purchase, the director now directly owns 600 shares in the company, valued at approximately $6,000. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Timothy M. Mayleben bought 7,000 shares of the stock in a transaction dated Wednesday, May 4th. The shares were purchased at an average cost of $14.85 per share, for a total transaction of $103,950.00. Following the completion of the purchase, the chief executive officer now owns 41,614 shares in the company, valued at $617,967.90. The disclosure for this purchase can be found here.

Esperion Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing and commercializing oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C. The Company’s segment is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.